An Overview of Male Osteoporosis

Melissa A. Burmeister, PhD; Timothy K. Fincher, PhD, RPh; Anthony M. Todd, PharmD; Kristopher G. Virga, PhD; Mary M. Maddox, PharmD Candidate 2022


US Pharmacist. 2021;46(6):18-24. 

In This Article


Despite all that is known about the risk factors, primary and secondary causes, incidence rates, and adverse outcomes following a high-trauma fracture, as well as the proven efficacy and general safety of multiple treatment options, osteoporosis continues to be underdiagnosed and undertreated in older men. Men are less likely to be evaluated and undergo treatment following a low-trauma fracture, which increases their risk of sustaining subsequent fractures.[20] Treatment rates remain low even after high-trauma fracture involving the hip.[20] Therefore, it is important for the pharmacist to foster increased awareness of male osteoporosis in the community. Identifying high-risk patients with comorbidities that share etiology or risk factors is a critical part of achieving earlier diagnosis of osteoporosis and ensuring its targeted management. Pharmacists serve as critical frontline HCPs who can advocate for regular bone-health screening in susceptible male patients and provide counsel on the benefits of leading a healthy lifestyle to prevent or delay bone loss and improve overall quality of life.